Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CD33 TRAILBody
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : FBVF
Deal Size : $3.1 million
Deal Type : Series A Financing
TRIO Pharmaceuticals Raises $3.1M to Advance Cancer Therapeutics Pipeline
Details : TRIO will use the net proceeds to advance cancer therapeutics pipeline, including CD33 TRAILBody in preclinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Product Name : CD33 TRAILBody
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
December 03, 2024
Lead Product(s) : CD33 TRAILBody
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : FBVF
Deal Size : $3.1 million
Deal Type : Series A Financing